InnoCare will discover compounds against up to 5 targets for Lilly, backing a deal worth up to $3.35 billion in milestones.
|Articles|March 10, 2021
Avantor, Inc.
Author(s)Avantor, Inc.
Strategically located, Avantor’s new Frankfurt, Germany, biorepository and archiving facility leverages 40+ years of expertise to offer:
- Customized solutions that accommodate samples from -196°C to +21°C
- 4000 m² lab & warehouse space
- 8400 m3 temperature & humidity-controlled storage
- Direct service to 90+ major EU cities and 300+ international destinations
- 24/7/365 monitoring, with backup, redundancy, and advanced security system.
Avantor, Inc.
Tel. 1.855.282.6967
Related to this article
FDA expands Winrevair’s label with HYPERION data, formalizes the use of non-animal testing methods, and Amgen reports positive Phase 3 results for dazodalibep in Sjögren disease.
The FDA has approved a label update for Merck's Winrevair (sotatercept-csrk) incorporating Phase 3 HYPERION data, showing a 76% reduction in clinical worsening events when added to background therapy in adults diagnosed with pulmonary arterial hypertension within the past year.
BIIE CEO Dr Stephen Wilson outlines rapid growth plans and a multidisciplinary technology stack targeting global clinical translation.
FDA's new rule formally recognizes non-animal methods like organoids and AI models as valid ways to support human drug testing.
Dazodalibep hit its phase 3 primary endpoint at week 48, building on phase 2 data showing a 6.3-point ESSDAI reduction versus placebo.
Glycomine's GLM101, an investigational liposomal mannose-1-phosphate substrate replacement therapy, has received FDA Breakthrough Therapy designation for PMM2-CDG, a rare glycosylation disorder with no approved treatments.
How early Phase I decisions can shape or compromise the regulatory and financing outcomes that define a biotech program's future.